GLP-1 Drugs Shrink Fast Food Market by 30%
Scott Galloway and Ed Elson's analysis on Prof G Markets reveals that roughly 30 million Americans (1 in 8 adults) are now on GLP-1 drugs, reducing fast food's addressable market by an estimated 27-30%, a structural rather than cyclical change.
Key Numbers
In a recent episode of Prof G Markets, analysts Scott Galloway and Ed Elson presented data that should unsettle fast food shareholders. According to their analysis, approximately 30 million Americans—or 1 in 8 US adults—are now taking GLP-1 drugs (such as Ozempic and Wegovy).
Details
Galloway explained that these drugs significantly suppress appetite, leading to a 27-30% reduction in the addressable market for fast food. He characterized this shift as "structural, not cyclical," meaning it represents a permanent change in consumer behavior rather than a temporary fluctuation.
Context
This development comes as fast food chains like McDonald's and Burger King face increasing competitive pressures. Conversely, pharmaceutical companies such as Eli Lilly (LLY) and Amazon (AMZN), which has entered the drug delivery space, stand to benefit from this trend.
What This Means for Investors
Investors in the fast food sector may need to reassess long-term growth assumptions, as the proliferation of GLP-1 drugs could continue to erode the consumer base. Meanwhile, this presents opportunities for pharmaceutical and healthcare services companies tied to these drugs.
Frequently Asked Questions
Found this useful? Share it